Related Experiment Video
Updated: Sep 20, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein
Paul A Reynolds1, Gromoslaw A Smolen, Rachel E Palmer
1Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA.
Abstract:
Desmoplastic small round cell tumor (DSRCT) is defined by a chimeric transcription factor, resulting from fusion of the N-terminal domain of the Ewing's sarcoma gene EWS to the three C-terminal zinc fingers of the Wilms' tumor suppressor WT1. Although DNA-binding sites have been defined for the uninterrupted WT1 zinc finger domains, the most prevalent isoforms of both WT1 and EWS-WT1 have an insertion of three amino acids [lysine, threonine, and serine (KTS)], which abrogates binding to known consensus sequences and transactivation of known target genes. Here, we used cDNA subtractive hybridization to identify an endogenous gene, LRRC15, which is specifically up-regulated after inducible expression of EWS-WT1(+KTS) in cancer cell lines, and is expressed within primary DSRCT cells. The chimeric protein binds in vitro and in vivo to a specific element upstream of LRRC15, leading to dramatic transcriptional activation. Mutagenesis studies define the optimal binding site of the (+KTS) isoform of EWS-WT1 as 5'-GGAGG(A/G)-3'. LRRC15 encodes a leucine-rich transmembrane protein, present at the leading edge of migrating cells, the expression of which in normal tissues is restricted to the invasive cytotrophoblast layer of the placenta; small interfering (siRNA)-mediated suppression of LRRC15 expression in breast cancer cells leads to abrogation of invasiveness in vitro. Together, these observations define the consequence of (KTS) insertion within WT1-derived zinc fingers, and identify a novel EWS-WT1 transcriptional target implicated in tumor invasiveness.
Insights
Desmoplastic small round cell tumor (DSRCT) involves a fusion gene EWS-WT1. Researchers identified LRRC15 as a novel target gene activated by EWS-WT1(+KTS), impacting tumor invasiveness.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Desmoplastic small round cell tumor (DSRCT) is characterized by the EWS-WT1 chimeric transcription factor.
- WT1 isoforms with a KTS insertion lose DNA-binding and transactivation capabilities.
- The precise function of EWS-WT1(+KTS) and its target genes remain incompletely understood.
Purpose of the Study:
- To identify novel target genes of the EWS-WT1(+KTS) fusion protein.
- To elucidate the functional consequences of EWS-WT1(+KTS) activity in DSRCT.
- To define the DNA-binding motif for the EWS-WT1(+KTS) isoform.
Main Methods:
- cDNA subtractive hybridization to identify upregulated genes.
- Inducible expression of EWS-WT1(+KTS) in cancer cell lines.
- In vitro and in vivo binding assays.
- Mutagenesis studies to define DNA binding sites.
- siRNA-mediated gene suppression to assess functional impact.
Main Results:
- LRRC15 was identified as a gene specifically upregulated by EWS-WT1(+KTS) and expressed in DSRCT.
- EWS-WT1(+KTS) directly binds to an upstream element of LRRC15, activating its transcription.
- The optimal binding site for EWS-WT1(+KTS) was determined as 5'-GGAGG(A/G)-3'.
- LRRC15, a transmembrane protein, promotes cell migration and its suppression reduces invasiveness in breast cancer cells.
Conclusions:
- The KTS insertion in WT1-derived zinc fingers alters DNA-binding specificity.
- LRRC15 is a novel transcriptional target of EWS-WT1(+KTS) implicated in DSRCT.
- LRRC15 plays a role in tumor cell invasiveness, representing a potential therapeutic target.
Related Concept Videos
Canonical Wnt Signaling Pathway
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Transcription Factors
Co-activators and Co-repressors

